Clinical trials
Breast Cancer Patients clinical trials
Below are recruiting breast cancer patients clinical trials, each written for real people, not researchers. We’re tracking 2,204 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06246968RecruitingPhase 1
Pembrolizumab plus tumor ablation for advanced triple-negative breast cancer
This study tests combining an immunotherapy drug (pembrolizumab, also called Keytruda) with a procedure that freezes or destroys cancer cells directly (called ablation). The goal is to see if this combination can help control triple-negative breast cancer that has spread or is inoperable.
Basking Ridge, New JerseyAges 18 years+ - NCT06178159RecruitingPhase 2
New drug combo before surgery for HER2-positive breast cancer
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05259410Recruiting
Time-restricted eating during breast cancer chemotherapy
This trial studies whether time-restricted eating (eating only within certain hours) during breast cancer chemotherapy is safe and helpful. Researchers want to see if it improves chemotherapy outcomes and side effects for people with stage I–III breast cancer.
Chicago, IllinoisAges 25–99 - NCT06223022Enrolling by invitation
Nurse phone calls after cancer treatment ends
This trial tests whether regular phone calls from a nurse can help patients after they finish their main cancer treatment. It focuses on breast, colorectal, or prostate cancer that was treated with a goal to cure.
UmeåAges 18 years+ - NCT06224673RecruitingPhase 2
Testing ARX788 for HER2-low advanced breast cancer
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06222788Recruiting
Plasma treatment during breast cancer lumpectomy
This trial tests a plasma treatment applied directly to the tumor site during a lumpectomy. It may help improve healing and reduce recurrence for people with early-stage breast cancer.
Montreal, QuebecAges 18 years+ - NCT06217874Recruiting
Collecting Samples and Data for Recurrent or Metastatic Breast Cancer
This study collects tissue samples and health information from people with breast cancer that has spread or come back. It aims to help researchers learn more about the disease and may lead to better treatments.
Rochester, MinnesotaAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06210776Recruiting
Study of T-DXd in Chinese breast cancer patients
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
BeijingAges 18 years+ - NCT05466786Recruiting
Testing gene changes and DNA damage in HER2-low breast cancer
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Guangzhou, GuangdongAges 18–70 - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06167694RecruitingPhase 1/Phase 2
Study of HRS-8080 and Dalpiciclib for advanced breast cancer
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
Beijing, Beijing MunicipalityAges 18–75 - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT06153836RecruitingPhase 2
Restoring nipple sensation after mastectomy
This trial is testing a surgical technique to reconnect nerves in the nipple and areola after a mastectomy, aiming to restore feeling. It is for women with breast cancer who are having a nipple-sparing mastectomy with implant reconstruction.
Jacksonville, FloridaAges 18 years+ - NCT06123988Recruiting
Fasting and exercise for advanced breast cancer
This study looks at whether fasting overnight and/or doing exercise can help improve fatigue and other quality-of-life measures in women with advanced hormone receptor positive breast cancer who are already taking a CDK4/6 inhibitor. Participation may involve following a fasting or exercise plan for a period of time.
Phoenix, ArizonaAges 18 years+ - NCT06113016RecruitingPhase 2
Preventing frailty with fisetin and exercise in breast cancer survivors
This study tests whether adding a supplement called fisetin to an exercise program can help prevent frailty in women who have finished chemotherapy for early-stage breast cancer. If you are postmenopausal, have completed chemo within the last year, and can walk a certain distance, you may qualify.
Alhambra, CaliforniaAges Any age - NCT06106477Recruiting
Intermittent fasting for women with early breast cancer
This trial studies whether a 14-hour night fast and 10-hour eating window can improve inflammation markers and quality of life in women with HR+/HER2- early breast cancer. You would start the fasting routine within three months of beginning hormone therapy.
Milwaukee, WisconsinAges 18 years+ - NCT06105684RecruitingPhase 2
Low-dose capecitabine for advanced breast cancer
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
Birmingham, AlabamaAges 60 years+ - NCT06121453Recruiting
Adherence support for metastatic breast cancer patients
This study tests a program to help people with metastatic breast cancer take their endocrine therapy, CDK4/6 inhibitors, and heart-related medications as prescribed. If you sometimes miss doses of these medicines, you may be able to join.
New York, New YorkAges 18–99 - NCT06127797Recruiting
MRI surveillance study for breast cancer survivors with dense breasts
This study is testing whether adding an MRI to your regular mammogram can help find any new breast cancers earlier. It is for women who have had breast cancer before and still have dense breast tissue, making mammograms harder to read.
Houston, TexasAges 18 years+
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer patients?
- Yes. Clin2 currently lists 2,204 recruiting breast cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.